First Midwest Bank Trust Division maintained its position in Amedisys Inc. (NASDAQ:AMED) during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 35,034 shares of the company’s stock at the end of the third quarter. First Midwest Bank Trust Division owned 0.10% of Amedisys worth $1,662,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of the stock. Nationwide Fund Advisors increased its stake in shares of Amedisys by 577.7% in the second quarter. Nationwide Fund Advisors now owns 123,964 shares of the company’s stock worth $6,258,000 after buying an additional 105,671 shares in the last quarter. Boston Advisors LLC increased its stake in shares of Amedisys by 52.5% in the second quarter. Boston Advisors LLC now owns 36,687 shares of the company’s stock worth $1,852,000 after buying an additional 12,624 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Amedisys by 202.1% in the second quarter. Jennison Associates LLC now owns 35,396 shares of the company’s stock worth $1,787,000 after buying an additional 23,681 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Amedisys by 21.6% in the second quarter. Teacher Retirement System of Texas now owns 3,780 shares of the company’s stock worth $191,000 after buying an additional 672 shares in the last quarter. Finally, Mason Street Advisors LLC acquired a new stake in shares of Amedisys during the second quarter worth $277,000. 95.96% of the stock is currently owned by institutional investors.
Amedisys Inc. (NASDAQ:AMED) opened at 41.66 on Monday. Amedisys Inc. has a 12 month low of $31.16 and a 12 month high of $55.16. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 33.98 and a beta of 1.45. The company’s 50-day moving average price is $42.68 and its 200 day moving average price is $48.26.
Amedisys (NASDAQ:AMED) last issued its earnings results on Thursday, November 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.44 by $0.08. Amedisys had a net margin of 2.93% and a return on equity of 11.94%. The business had revenue of $361.60 million for the quarter, compared to the consensus estimate of $361.08 million. During the same period in the previous year, the firm earned $0.34 EPS. The company’s revenue was up 10.8% compared to the same quarter last year. Analysts forecast that Amedisys Inc. will post $1.49 EPS for the current fiscal year.
A number of brokerages have weighed in on AMED. Jefferies Group reaffirmed a “buy” rating and issued a $50.00 target price (down previously from $59.00) on shares of Amedisys in a report on Tuesday, November 1st. Mizuho raised Amedisys from a “neutral” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Monday, November 7th. Zacks Investment Research raised Amedisys from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $50.29.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.